Wells Fargo added Aerovate Therapeutics to its Q2 Tactical Ideas List. Based on its deep dive of the trial’s key risks and merits, the firm is confident in positive data from IMPAHCT. In its scenario analysis, Wells sees shares up 60% in its base case, with 100%+ upside in its bull case. Aerovate remains one of the firm’s top picks. Wells has an Overweight rating on the shares with a price target of $35.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTE:
- Aerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial Growth
- Aerovate Therapeutics Announces Upcoming Investor Presentation Access
- Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
- Aerovate Therapeutics price target raised to $50 from $27 at BTIG
- Aerovate Therapeutics reports FY23 EPS (74c), consensus (71c)
